PRNewsWire
07 Nov 2025, 13:30 UTC · 45w ago
Verdict
Headline leans bullish. We score JNJ +0.90 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has approved DARZALEX Faspro as the first and only treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).
More positive than 91% of claims this week
DARZALEX Faspro is co-formulated with Halozyme's ENHANZE drug delivery technology.
Continue reading
5 related stories
More positive than 94% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 76% of claims this week
The approval shifts the standard of care for HR-SMM from 'active monitoring' to therapeutic intervention.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Received FDA approval for DARZALEX Faspro as the first and only treatment for high-risk smoldering multiple myeloma.
More positive than 85% of ticker scores this week
FDA approval of a new indication for a product using its ENHANZE technology expands its market reach.
More positive than 78% of relationship scores this week
[a_to_b] Halozyme supplies its ENHANZE drug delivery technology used in Johnson & Johnson's DARZALEX Faspro.
More positive than 35% of relationship scores this week
[mutual] Halozyme has licensed its ENHANZE technology to Bristol-Myers Squibb.
More positive than 35% of relationship scores this week
[mutual] Halozyme has licensed its ENHANZE technology to Eli Lilly.
More positive than 35% of relationship scores this week
[mutual] Halozyme has licensed its ENHANZE technology to Pfizer.
More positive than 35% of relationship scores this week
[mutual] Halozyme has licensed its ENHANZE technology to AbbVie.
More positive than 16% of relationship scores this week
[mutual] Halozyme has partnered commercial products with McDermott Laboratories, an affiliate of Viatris.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
2d ago
+44.4%
Price agrees with the score
$269.99 vs $186.97 close before publication (Nov 6) · not market-adjusted
JNJ chart →
